OBI Pharma (4174) — Cash Flow-to-Debt Ratio

Latest as of December 2025: -0.69x

OBI Pharma (4174) has a Cash Flow-to-Debt Ratio of -0.69x as of December 2025, meaning its operating cash flow of NT$-479.25 Million could theoretically repay -1% of its total liabilities (NT$696.13 Million) in one year. Explore OBI Pharma long-term investment allocation to see how much of total assets are deployed in long-term investments.

CF-to-Debt Ratio

-0.69x
Operating CF / Total Liabilities

Operating Cash Flow

NT$-479.25 Million
TWD

Total Liabilities

NT$696.13 Million
TWD

Data as of

Dec 2025
Most recent filing

OBI Pharma Cash Flow-to-Debt Ratio (2011–2025)

Historical debt coverage capacity for OBI Pharma across 15 annual periods. Also explore OBI Pharma asset portfolio for the complete picture of this company's asset base.

Annual Cash Flow-to-Debt Ratio for OBI Pharma (2011–2025)

Year-by-year debt coverage analysis for OBI Pharma. For market capitalisation and broader financial context, see 4174 market cap.

Year CF-to-Debt Ratio Operating CF (TWD) Total Liabilities YoY Change
2025 -2.90x NT$-2.02 Billion NT$696.13 Million ▼ -31.9%
2024 -2.20x NT$-1.83 Billion NT$833.38 Million ▲ +13.4%
2023 -2.54x NT$-1.65 Billion NT$650.45 Million ▲ +21.9%
2022 -3.26x NT$-1.62 Billion NT$497.57 Million ▼ -88.4%
2021 -1.73x NT$-1.06 Billion NT$615.95 Million ▲ +46.1%
2020 -3.21x NT$-1.61 Billion NT$502.09 Million ▼ -40.6%
2019 -2.28x NT$-1.05 Billion NT$459.14 Million ▲ +37.7%
2018 -3.66x NT$-864.31 Million NT$236.03 Million ▲ +57.1%
2017 -8.54x NT$-1.11 Billion NT$129.66 Million ▼ -70.0%
2016 -5.02x NT$-840.10 Million NT$167.32 Million ▼ -71.3%
2015 -2.93x NT$-372.20 Million NT$127.00 Million ▲ +72.1%
2014 -10.49x NT$-464.22 Million NT$44.24 Million ▼ -317.7%
2013 -2.51x NT$-104.16 Million NT$41.46 Million ▲ +5.2%
2012 -2.65x NT$-117.64 Million NT$44.40 Million ▲ +92.6%
2011 -35.61x NT$-508.22 Million NT$14.27 Million
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.